This report treats the video as a source lead, not as a prescription. The strongest part of Dr. Rachel Rubin’s message is well supported: genitourinary syndrome of menopause is common, underdiscussed and treatable; low-dose vaginal estrogen is guideline-supported for appropriate patients with GSM symptoms and recurrent UTIs; and sexual pain, desire and orgasm deserve ordinary medical attention instead of embarrassment or dismissal. The weaker part is not the topic — it is the occasional podcast-style overstatement that turns guideline language into slogans such as “safe for everybody” or “better than Viagra.”
Medical caution
This article is source review, not medical advice, diagnosis, dosing guidance or a recommendation to start hormones, testosterone, DHEA, ospemifene, compounded products or supplements. People with postmenopausal bleeding, pelvic pain, recurrent UTI symptoms, cancer history, clot/stroke history, pregnancy/breastfeeding questions, medications or complex conditions should speak with a qualified clinician.
The video being checked
The source video is Intimacy Expert: The Masterclass On Better Sex, Orgasms & Pleasure | Dr Rachel Rubin on The Diary Of A CEO. The fetched transcript runs about 1 hour 48 minutes and covers menopause, sexual medicine, vaginal hormones, orgasm, libido, pain with sex, pelvic floor dysfunction, pornography, relationships and medical education gaps.
Dr. Rubin’s official site describes her practice as a nationally recognized urology and sexual medicine practice seeing patients of all genders for desire, arousal, orgasm, pain, erectile dysfunction, urinary tract and vaginal infections, incontinence, prolapse, perimenopause and menopause symptoms. Her about page says she was involved in the development and release of AUA medical guidelines for genitourinary syndrome of menopause.
The central thesis
Rubin’s central public-health thesis is that sexual medicine is not a side topic. For many women, it overlaps with urinary infections, tissue health, pain, relationships, cancer survivorship, childbirth, lactation, menopause, medication side effects and basic anatomy education.
That thesis is serious. It also needs careful translation. A podcast can say “this is better than Viagra.” A medical report should say: for selected hypoestrogenic patients with GSM, local low-dose vaginal estrogen is guideline-supported for vaginal dryness, irritation, painful sex and recurrent UTI prevention; it is not the same drug, indication or evidence pathway as Viagra.
What GSM is — and why it matters
Genitourinary syndrome of menopause, or GSM, is the modern term for a cluster of genital, urinary and sexual symptoms linked to reduced estrogen and androgen effects in vulvovaginal and urinary tissues. Older labels such as “vaginal atrophy” were too narrow because the problem may involve the vulva, vagina, urethra, bladder, sexual function and recurrent infection risk.
Common GSM-related problems include vaginal dryness, burning, irritation, painful sex, urinary urgency, frequency, dysuria and recurrent urinary tract infections. NCBI’s StatPearls overview describes GSM as common, progressive, underdiagnosed and undertreated. The AUA/SUFU/AUGS guideline frames GSM as a clinical condition requiring identification, counseling, treatment and follow-up, not a private embarrassment.
What the video gets substantially right
- GSM is real and common. It is not simply “normal aging” that patients must tolerate. It is a recognized hypoestrogenic condition affecting quality of life, urinary health and sexual function.
- Local low-dose vaginal estrogen is mainstream treatment. The 2025 AUA/SUFU/AUGS guideline says clinicians should offer local low-dose vaginal estrogen for GSM-related vulvovaginal discomfort, irritation, dryness and/or dyspareunia.
- Recurrent UTI prevention is a major evidence point. The same guideline says clinicians should recommend local low-dose vaginal estrogen for patients with GSM and recurrent urinary tract infections to reduce future UTI risk.
- There are nonhormonal tools too. Vaginal moisturizers and lubricants are guideline-supported for dryness and dyspareunia, alone or with other therapies.
- Painful sex has multiple causes. Hormonal tissue changes, vulvar skin disease, pelvic-floor muscle dysfunction, nerve/spine issues, endometriosis and psychological or relationship factors can overlap.
- The orgasm gap is not just biology. A 2024 scoping review of the partnered-orgasm gap reports that women’s orgasm rates increase substantially when sexual activity includes clitoral stimulation, pointing to social, educational and partner-behaviour factors as well as anatomy.
- Women produce testosterone. Testosterone is not only a “male hormone.” But the evidence-supported medical use is narrow: carefully assessed postmenopausal women with hypoactive sexual desire disorder, under monitoring — not broad anti-aging or wellness marketing.
Where the video needs nuance
- “Safe for everybody” is too broad. Low-dose vaginal estrogen is generally treated very differently from systemic hormone therapy and is guideline-supported in many settings. But patients with unexplained bleeding, breast-cancer history, aromatase-inhibitor therapy, complex clot/stroke history or unusual symptoms need clinician-specific risk discussion.
- Breast-cancer survivors deserve shared decision-making. ACOG says nonhormonal methods should generally be considered first-line for people with a history of estrogen-dependent breast cancer. If symptoms persist, low-dose vaginal estrogen may be considered after risk-benefit discussion; for aromatase-inhibitor users, the decision should involve the patient, gynecologist and oncologist.
- “Prevents death from UTIs” is not the same as “mortality-proven for everyone.” Recurrent UTIs in older adults can become serious. Preventing UTIs matters. But the evidence should be reported as reduced recurrent UTI risk, not as a guaranteed death-prevention intervention for all women.
- “Better than Viagra” is rhetorical shorthand. Viagra treats erectile dysfunction through a different mechanism. Vaginal estrogen treats hypoestrogenic tissue changes. For a patient whose sex is painful because tissues are dry, fragile or irritated, vaginal therapy may be more relevant than arousal drugs — but that is not a head-to-head universal comparison.
- Compounded and wellness-hormone markets need caution. Guideline-supported hormone care is not the same as influencer-driven “hormone optimization,” unmonitored testosterone, pellets, or broad anti-aging claims.
Evidence map
| Topic | Evidence status | Practical meaning |
|---|---|---|
| GSM diagnosis and treatment | Guideline-supported | Ask a clinician about GSM if symptoms include dryness, irritation, painful sex, urgency, frequency or recurrent UTIs. |
| Local low-dose vaginal estrogen for GSM symptoms | AUA/SUFU/AUGS strong recommendation, evidence level C | Mainstream option for appropriate patients; choice of cream, tablet, insert or ring depends on patient factors and clinician guidance. |
| Local low-dose vaginal estrogen for recurrent UTIs in GSM | AUA/SUFU/AUGS moderate recommendation, evidence level B; meta-analysis support | Important non-antibiotic prevention discussion for peri/postmenopausal or hypoestrogenic patients with recurrent UTIs. |
| Moisturizers/lubricants | Guideline-supported nonhormonal therapy | Useful first-line or adjunctive tools; product comfort and irritant avoidance matter. |
| Laser/radiofrequency devices for GSM | AUA says evidence does not support routine use for key GSM outcomes | Treat as experimental outside clinical trials or careful shared decision-making. |
| Systemic testosterone for women | Consensus-supported only for HSDD in postmenopausal women after assessment | Not a general energy, mood, marriage, weight-loss or anti-aging treatment. |
| Pelvic-floor PT for sexual pain | Useful for selected patients; evidence varies by condition | Consider referral when pain, tightness, vaginismus, pelvic pain or muscle dysfunction is suspected. |
The supporting theory: sexual health is biopsychosocial
The deeper theory behind this area of medicine is not “one hormone fixes everything.” It is that sexual function sits at the intersection of biology, tissue health, anatomy, pain processing, hormones, vascular function, mood, medication effects, trauma, relationship dynamics, culture and education.
That matters because a patient who says “I have low desire” or “sex hurts” may not need one standard answer. Possible contributors include GSM, pelvic-floor overactivity, vulvodynia, postpartum/lactation changes, SSRI or other medication effects, thyroid disease, depression, stress, relationship conflict, past trauma, endometriosis, dermatologic disease, urinary symptoms, sleep disruption or unrealistic sexual scripts learned from pornography. A serious sexual-medicine clinician does not reduce all of that to either “it’s in your head” or “take this hormone.”
Similar doctors and public voices
Rubin is part of a broader wave of clinicians bringing menopause and sexual medicine into public conversation. They overlap, but they are not identical.
| Clinician / voice | Typical lane | How to read them carefully |
|---|---|---|
| Rachel Rubin, MD | Urology, sexual medicine, GSM, orgasm, urinary health, hormone access | Strong guideline overlap on GSM/vaginal estrogen; advocacy language needs translation into patient-specific medical advice. |
| Kelly Casperson, MD | Urology, sexuality, hormones, women’s pleasure, menopause conversation | Similar sexual-medicine advocacy; distinguish clinician education from personal prescription. |
| Lauren Streicher, MD | Menopause and sexual medicine education; clinical and podcast/public writing | Useful clinical menopause framing; still verify product-specific or intervention-specific claims. |
| Mary Claire Haver, MD | OB/GYN menopause education with lifestyle/metabolic/wellness audience | Broad menopause awareness; separate standard-care hormone discussion from branded wellness ecosystem. |
| Louise Newson, MD | UK menopause/HRT advocacy, public education and hormone-access campaign | Important public-health pressure around undertreatment; still apply individual risk/benefit and local guidelines. |
| Jen Gunter, MD | OB/GYN science communication and wellness-claim debunking | Useful counterweight against hype; often more skeptical of broad hormone/wellness narratives. |
What a patient should ask a clinician
- Could my symptoms fit GSM, recurrent UTI, pelvic-floor dysfunction, vulvar skin disease, endometriosis, medication effects, infection, STI, trauma history or another condition?
- Do I need an exam, urine culture, STI testing, pelvic-floor assessment, dermatology/vulvar specialist referral, urology, gynecology or sexual-medicine referral?
- Would nonhormonal moisturizers/lubricants be enough, or should I discuss local low-dose vaginal estrogen, vaginal DHEA, ospemifene or another option?
- If I have a history of breast cancer, endometrial cancer, unexplained bleeding, clot/stroke history, liver disease or complex medication use, who should be involved in the risk discussion?
- If low desire is the concern, is this distressing HSDD, pain avoidance, relationship mismatch, depression/stress, sleep loss, medication effect, hormone deficiency or something else?
- If testosterone is discussed, what indication is being treated, what formulation is being used, how will levels and side effects be monitored, and why is this not simply wellness marketing?
- If a laser, radiofrequency device, supplement, peptide, compounded pellet or expensive clinic package is suggested, what guideline supports it and what are the alternatives?
Red flags
- Anyone claiming one hormone “fixes all women.”
- Any clinician or influencer selling fear of menopause as a funnel into unmonitored pellets, compounded hormones or expensive packages.
- Any dismissal of sexual pain as “normal,” “just aging,” or “just relationship problems” without assessment.
- Any postmenopausal bleeding being treated casually without evaluation.
- Any recurrent UTI pattern being repeatedly treated with antibiotics without asking why it keeps happening.
- Any claim that a podcast clip is enough to self-prescribe hormones or testosterone.
Managing expectations
Rubin’s strongest point is that women’s sexual and urinary health has been under-prioritized. The source trail supports that this is a real field with real guidelines, real therapies and real under-treatment. The most important example is GSM: when the biology fits, local low-dose vaginal estrogen is not fringe. It is mainstream, guideline-supported care.
The careful conclusion is this: Dr. Rachel Rubin is right that sexual medicine belongs inside serious medicine. She is also speaking in podcast language. Patients should convert the message into clinician-guided questions, not self-treatment.
Source links
- Original YouTube video: Diary of a CEO with Dr. Rachel Rubin
- Local transcript of the YouTube interview
- Local YouTube metadata extract
- Dr. Rachel Rubin official about page
- AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause
- ISSWSH — International Society for the Study of Women’s Sexual Health
- ACOG: Urogenital symptoms in individuals with estrogen-dependent breast-cancer history
- NCBI Bookshelf / StatPearls: Genitourinary Syndrome of Menopause
- PubMed: Estrogen for prevention of recurrent UTIs in postmenopausal women — meta-analysis
- PubMed: Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study
- PubMed: ISSWSH guideline for systemic testosterone in women with HSDD
- PubMed: Global Consensus Position Statement on testosterone therapy for women
- PubMed: Gender gap in partnered orgasm — scoping review
- PubMed: Female sexual medicine in medical school curricula
- Local source note
Health source library
Back to Managing Expectations Health for source-grounded reviews of medical claims, doctor interviews, papers and viral narratives.
Back to Health